RedHill Shares Gain As European Commission Grants Orphan Drug Status To NTM Infections Candidate
The European Commission has granted Orphan Drug Designation to RedHill Biopharma’s (NASDAQ: RDHL) lead asset RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.